IL126626A0 - Novel antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis - Google Patents

Novel antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis

Info

Publication number
IL126626A0
IL126626A0 IL12662697A IL12662697A IL126626A0 IL 126626 A0 IL126626 A0 IL 126626A0 IL 12662697 A IL12662697 A IL 12662697A IL 12662697 A IL12662697 A IL 12662697A IL 126626 A0 IL126626 A0 IL 126626A0
Authority
IL
Israel
Prior art keywords
absent
methods
polynucleotides encoding
residues
inhibiting angiogenesis
Prior art date
Application number
IL12662697A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/643,219 external-priority patent/US5801146A/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL126626A0 publication Critical patent/IL126626A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12662697A 1996-05-03 1997-05-05 Novel antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis IL126626A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/643,219 US5801146A (en) 1996-05-03 1996-05-03 Compound and method for inhibiting angiogenesis
US08/832,087 US5981484A (en) 1996-05-03 1997-04-03 Antiangiogenic peptides and methods for inhibiting angiogenesis
PCT/US1997/007700 WO1997041824A2 (en) 1996-05-03 1997-05-05 Antiangiogenic peptides derived from plasminogen

Publications (1)

Publication Number Publication Date
IL126626A0 true IL126626A0 (en) 1999-08-17

Family

ID=27094211

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12662697A IL126626A0 (en) 1996-05-03 1997-05-05 Novel antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis

Country Status (16)

Country Link
US (3) US6057122A (es)
EP (2) EP0910571B1 (es)
JP (1) JP4426650B2 (es)
CN (1) CN1152962C (es)
AT (1) ATE299888T1 (es)
AU (1) AU724077B2 (es)
BR (1) BR9708911A (es)
CZ (1) CZ298260B6 (es)
DE (1) DE69733756T2 (es)
DK (1) DK0910571T3 (es)
ES (1) ES2246513T3 (es)
HK (1) HK1021191A1 (es)
HU (1) HU224827B1 (es)
IL (1) IL126626A0 (es)
NZ (1) NZ332319A (es)
WO (1) WO1997041824A2 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
AU7951798A (en) * 1997-06-26 1999-01-19 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
EP1047771B1 (en) * 1998-01-12 2003-04-23 G.D. Searle & Co. Method of refolding angiostatin
AU764277B2 (en) * 1998-05-22 2003-08-14 Abbvie Inc. Peptide antiangiogenic drugs
US6632961B1 (en) 1998-05-22 2003-10-14 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US6774211B1 (en) 1998-05-22 2004-08-10 Abbott Laboratories Peptide antiangiogenic drugs
WO1999061466A1 (en) * 1998-05-22 1999-12-02 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US6716963B1 (en) 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
AU3959499A (en) * 1998-05-28 1999-12-13 Korea Green Cross Corporation Process of purifying angiogenesis inhibitors
AU751283B2 (en) * 1998-07-14 2002-08-08 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin
US7317003B2 (en) 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
KR20000018933A (ko) * 1998-09-07 2000-04-06 김승수 내피세포 성장억제 활성을 가지는 사람 프로트롬빈 크링글단백질 및 이를 암호하는 유전자
US6356782B1 (en) * 1998-12-24 2002-03-12 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US6371904B1 (en) * 1998-12-24 2002-04-16 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US9669113B1 (en) 1998-12-24 2017-06-06 Devicor Medical Products, Inc. Device and method for safe location and marking of a biopsy cavity
US6465424B1 (en) * 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
ES2209885T3 (es) * 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
JP4209086B2 (ja) * 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド 長期持続性抗新脈管形成ペプチド
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
SG87828A1 (en) * 1999-09-03 2002-04-16 Univ Singapore Small peptides having potent anti-angiogenic activity
US6576610B1 (en) * 1999-10-04 2003-06-10 Nuvas, Llc Use of a context-dependent functional entity to enhance the efficacy of an agent
US6777535B1 (en) 1999-11-22 2004-08-17 Abbott Laboratories N-alkylated peptides having antiangiogenic activity
CO5261544A1 (es) * 1999-11-22 2003-03-31 Abbott Lab Peptidos n-alquilados que tienen actividad antiangiogenica
US6753408B1 (en) 1999-11-22 2004-06-22 Fortuna Haviv Peptides having antiangiogenic activity
US6485740B1 (en) * 2000-03-14 2002-11-26 Yutoku Pharmaceutical Ind., Co., Ltd. Transdermal methotrexate preparations
CA2415923C (en) 2000-07-12 2011-10-25 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
JP2004508048A (ja) 2000-09-05 2004-03-18 カロリンスカ　イノベーションズ　アクティーエボラーグ 内皮細胞増殖阻害物質に関する材料と方法
US20020159992A1 (en) * 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
PE20020376A1 (es) * 2000-09-29 2002-05-13 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
AU2002239366A1 (en) 2000-11-28 2002-06-11 Geetha Kassam Anti-angiogenic polypeptides
ES2422301T3 (es) * 2000-12-19 2013-09-10 Res Dev Foundation Transferencia de gen mediada por vector lentiviral y usos de la misma
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
US20040132644A1 (en) * 2001-10-16 2004-07-08 The Procter & Gamble Company Composition and method for treating diabetes
CA2514873C (en) * 2002-12-13 2012-01-03 David Waisman Compositions and methods for inhibiting tumor growth and metastasis
US20050053993A1 (en) * 2002-12-18 2005-03-10 Davidson Donald J. Uses of an endothelial cell receptor
JP4681548B2 (ja) 2003-07-22 2011-05-11 アステックス・セラピューティクス・リミテッド ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
MXPA04005080A (es) * 2004-05-27 2005-11-30 Aspid S A De C V Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona.
TWI285647B (en) * 2004-08-20 2007-08-21 Univ Nat Chunghsing Prevention, treatment and detection of porcine progressive atrophic rhinitis
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
MX2007008781A (es) * 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
CN101541743A (zh) 2006-11-08 2009-09-23 于崇曦 多肽及相关化合物的透皮给药系统
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
WO2009100617A1 (zh) * 2008-02-04 2009-08-20 Shanghai First People's Hospital 抑制血管新生的多肽及其应用
CN102459313A (zh) 2009-05-08 2012-05-16 上海泰飞尔生化技术有限公司 多肽和多肽相关化合物的高穿透力前药组合物
EP2435562A1 (en) 2009-05-26 2012-04-04 Biolex Therapeutics, Inc. Compositions and methods for production of aglycosylated plasminogen
RU2564131C2 (ru) * 2009-07-10 2015-09-27 ТромбоДженикс НВ Варианты плазминогена и плазмина
BR112013017172A2 (pt) 2011-01-05 2016-10-11 Thrombogenics Nv variantes de plasminogênio e plasmina
KR20140064841A (ko) 2011-08-12 2014-05-28 쓰롬보제닉스 엔.브이. 플라스미노겐 변이체 및 플라스민 변이체
KR101676690B1 (ko) 2015-08-04 2016-11-16 (주) 에빅스젠 Vegf 유도-혈관신생 억제효과를 갖는 테트라펩티드 및 이의 용도
KR101644440B1 (ko) * 2015-12-10 2016-08-01 (주) 에빅스젠 개선된 혈관신생 억제용 펩티드와 이를 유효성분으로 함유하는 혈관신생과 관련된 질환의 예방 및 치료용 조성물
JP6876066B2 (ja) 2015-12-18 2021-05-26 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 子宮膣部びらんを予防及び治療するための方法
CA3008466C (en) * 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
EP3556382A4 (en) 2016-12-15 2020-12-09 Talengen International Limited METHOD OF PREVENTION AND TREATMENT OF SKIN FIBROSIS
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
JP6651493B2 (ja) * 2017-12-05 2020-02-19 チョンシー ユー ペプチド及び関連化合物の経皮送達システム

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5288489A (en) * 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
WO1995029243A1 (en) * 1994-04-26 1995-11-02 Pharmacia & Upjohn Company Mac-1 i-domain protein useful in blocking adhesion and migration of neutrophils
JP3880064B2 (ja) * 1994-04-26 2007-02-14 ザ チルドレンズ メディカル センター コーポレイション アンジオスタチンおよび血管形成の抑制におけるその使用
AU710612B2 (en) * 1995-12-13 1999-09-23 Abbvie Inc. Endothelial cell proliferation inhibitor and method of use
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use

Also Published As

Publication number Publication date
AU724077B2 (en) 2000-09-14
CN1223690A (zh) 1999-07-21
WO1997041824A3 (en) 1998-01-08
EP0910571B1 (en) 2005-07-20
BR9708911A (pt) 1999-08-03
DE69733756D1 (de) 2005-08-25
CZ298260B6 (cs) 2007-08-08
AU3060697A (en) 1997-11-26
HUP9903530A3 (en) 2001-12-28
US5972896A (en) 1999-10-26
CN1152962C (zh) 2004-06-09
JP2002502235A (ja) 2002-01-22
EP1612272A3 (en) 2007-05-02
WO1997041824A2 (en) 1997-11-13
EP1612272A2 (en) 2006-01-04
ES2246513T3 (es) 2006-02-16
HUP9903530A2 (hu) 2000-02-28
EP0910571A2 (en) 1999-04-28
EP1612272B1 (en) 2011-06-22
DE69733756T2 (de) 2006-06-01
HK1021191A1 (en) 2000-06-02
CZ342698A3 (cs) 1999-05-12
US6057122A (en) 2000-05-02
DK0910571T3 (da) 2005-10-31
HU224827B1 (hu) 2006-02-28
ATE299888T1 (de) 2005-08-15
US6251867B1 (en) 2001-06-26
JP4426650B2 (ja) 2010-03-03
NZ332319A (en) 2000-09-29

Similar Documents

Publication Publication Date Title
IL126626A0 (en) Novel antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
Sanger et al. The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates
CA2277832A1 (en) Cyclic peptides that bind to urokinase-type plasminogen activator receptor
ZW6189A1 (en) Anti-aggregatory peptides
CA2265900A1 (en) Improved solid-phase peptide synthesis and agent for use in such synthesis
AU5019093A (en) Peptidyl activated ketone inhibitors containing natural and unnatural peptide sequences
CA2248772A1 (en) Novel peptides which inhibit complement activation
EP0162813A3 (en) Pharmaceutical compositions containing a dipeptide
CA2066913A1 (en) Novel binding peptides
NZ333606A (en) Isolated peptides derived from MAGE-2
WO1996016982A3 (en) Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
CA2221865A1 (en) Bradykinin analogs as selective thrombin inhibitors
HU9503593D0 (en) Factor vii-derived peptides
AU2864092A (en) Propargyl glycine amino propargyl diol compounds for treatment of hypertension
GR3017297T3 (en) Novel substrate peptides.
Barelli et al. Further characterization of a neurotensin-degrading neutral metalloendopeptidase from rat brain
HU0102040D0 (en) Purified gabapentine binding protein
EP0328089A3 (en) Reduced size lhrh analogs
NZ511747A (en) Regulatory/unfolding peptides of ezrin
Dufour et al. Proteolytic specificity of chicken cathepsin L on bovine β-casein
DE3665462D1 (en) Pharmacologically active peptides
JPS572213A (en) Cosmetic
Olma et al. Synthesis and binding properties of deltorphin I analogues containing (R) and (S)-α-hydroxymethylnaphtylalanine.
HK1003839A1 (en) Process for preparing peptides having a c-terminal proline amide
EP1225184A4 (en) HUMAN ANTITHROMBIN VARIANTS